Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP)’s share price traded down 2.2% during trading on Monday . The stock traded as low as $11.08 and last traded at $11.24, with a volume of 289,145 shares. The stock had previously closed at $11.49.

Several equities analysts have commented on the stock. Guggenheim reissued a “buy” rating and set a $29.00 target price on shares of Sucampo Pharmaceuticals in a research report on Wednesday, May 4th. Mizuho upgraded shares of Sucampo Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $14.00 price target for the company in a research note on Wednesday, April 20th. Leerink Swann restated a “market perform” rating and set a $17.00 price target on shares of Sucampo Pharmaceuticals in a research note on Thursday, March 17th. Roth Capital restated a “buy” rating on shares of Sucampo Pharmaceuticals in a research note on Wednesday, April 20th. Finally, Maxim Group restated a “buy” rating and set a $26.00 price target on shares of Sucampo Pharmaceuticals in a research note on Sunday, May 1st. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $21.00.

The firm’s 50-day moving average price is $11.35 and its 200-day moving average price is $12.17. The firm has a market capitalization of $477.46 million and a price-to-earnings ratio of 22.18.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its earnings results on Wednesday, May 4th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.02. The firm earned $47.20 million during the quarter, compared to the consensus estimate of $44.11 million. The company’s quarterly revenue was up 60.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.14 EPS. Equities research analysts predict that Sucampo Pharmaceuticals Inc. will post $1.02 earnings per share for the current fiscal year.

Several hedge funds and institutional investors have recently modified their holdings of SCMP. NorthCoast Asset Management LLC purchased a new position in shares of Sucampo Pharmaceuticals during the fourth quarter valued at about $1,130,000. Globeflex Capital L P increased its position in shares of Sucampo Pharmaceuticals by 76.5% in the fourth quarter. Globeflex Capital L P now owns 65,588 shares of the biopharmaceutical company’s stock valued at $1,134,000 after buying an additional 28,431 shares in the last quarter. Shell Asset Management Co. purchased a new position in shares of Sucampo Pharmaceuticals during the fourth quarter valued at about $1,324,000. Systematic Financial Management LP increased its position in shares of Sucampo Pharmaceuticals by 18.1% in the fourth quarter. Systematic Financial Management LP now owns 101,745 shares of the biopharmaceutical company’s stock valued at $1,759,000 after buying an additional 15,590 shares in the last quarter. Finally, GSA Capital Partners LLP increased its position in shares of Sucampo Pharmaceuticals by 8.5% in the fourth quarter. GSA Capital Partners LLP now owns 219,881 shares of the biopharmaceutical company’s stock valued at $3,802,000 after buying an additional 17,172 shares in the last quarter.

Sucampo Pharmaceuticals, Inc is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders. It generates revenue from product royalties, development milestone payments, product sales and clinical development activities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.